Journal of Environmental and Public Health / 2020 / Article / Tab 5

Research Article

Antibiotic Resistance Profile of Bacteria Isolated from Wastewater Systems in Eastern Ethiopia

Table 5

Antibiotic resistance among isolates of environmental resistance indicator bacterial species by monitoring site.

SiteResistance phenotypeNo. testedNumber and (%) resistant to antibiotic testedMARI mean (SD)
AMPAMC30CAZ30CFPGEN10AMIKLVL5CIP5MRP10SxT25

ASSE. coli6129 (47.5)28 (45.9)30 (49.2)19 (31.2)10 (16.4)13 (21.3)14 (22.9)17 (27.87)11 (18)15 (24.6)0.30 (0.03)
E. faecalis6026 (43.3)8 (13.3)13 (21.6)15 (25)16 (26.7)0.26 (0.03)
E. faecium5825 (43.1)11 (18.9)12 (20.7)15 (25.9)18 (31)0.28 (0.04)
P. aeruginosa5925 (42.37)23 (39)12 (20.3)12 (20.3)12 (20.3)16 (27.1)11 (18.6)0.27 (0.03)
Aeromonas spp.5819 (32.8)21 (36.2)12 (20.7)17 (29.31)24 (41.4)0.32 (0.04)

WSPE. coli5228 (53.8)25 (48.1)27 (51.9)19 (36.5)13 (25)14 (26.9)17 (32.7)19 (36.54)15 (28.9)15 (28.9)0.37 (0.03)
E. faecalis4826 (54.2)11 (22.9)14 (29.2)17 (35.4)17 (35.4)0.35 (0.03)
E. faecium4823 (47.9)11 (22.9)13 (27.1)17 (35.4)21 (43.7)0.35 (0.03)
P. aeruginosa4824 (50)20 (41.7)9 (18.75)48 (29.2)14 (29.2)15 (31.3)13 (27.1)0.32 (0.04)
Aeromonas spp.4816 (33.3)19 (39.6)13 (27.1)18 (37.5)29 (60.4)0.40 (0.04)

STSE. coli3836 (94.7)30 (78.9)33 (86.8)31 (81.6)15 (39.5)17 (44.7)21 (55.26)19 (50)16 (42.1)29 (76.32)0.65 (0.03)
E. faecalis3633 (91.7)13 (36.1)19 (52.8)21 (58.3)22 (61.1)0.60 (0.04)
E. faecium3632 (88.9)18 (50)23 (63.9)23 (63.9)27 (75)0.68 (0.04)
P. aeruginosa3628 (77.8)28 (77.8)16 (44.4)17 (47.2)17 (47.22)21 (58.3)17 (47.2)0.57 (0.03)
Aeromonas spp.3626 (72.2)29 (80.6)19 (52.8)25 (69.4)25 (69.4)0.69 (0.4)

ASS: activated sludge system, WSP: waste stabilization pond, STS: septic tank system, AMP: ampicillin, AMC30: amoxicillin/clav, CAZ30: ceftazidime, CFP, cefepime, GEN10: gentamicin, AMIK: amikacin, LVL5: levofloxacin, CIP5: ciprofloxacin, MRP10: meropenem, SxT25: Co-Trimoxazole.

We are committed to sharing findings related to COVID-19 as quickly as possible. We will be providing unlimited waivers of publication charges for accepted research articles as well as case reports and case series related to COVID-19. Review articles are excluded from this waiver policy. Sign up here as a reviewer to help fast-track new submissions.